Scholarlink

<p>The efficacy and prognosis of epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) patients with brain metastases (BMs) are poor. The third-generation EGFR-tyrosine kinase inhibitor proved to have better intracranial efficacy, which combined with anti-angiogenic drugs can further improve the efficacy. We conducted a single-arm, phase 2 clinical study (GASTO-1063) to explore the intracranial efficacy of aumolertinib plus anlotinib for NSCLC with BMs, with 87 patients enrolled. Median intracranial progression-free survival (PFS) was 30.2 months, median overall PFS was 22.5 months, and median overall survival was not reached. The intracranial objective response rate and intracranial disease control rate were 71.3% and 93.1%. Patients with exon 19 deletion or wild-type <i>TP53</i> exhibited significantly longer intracranial PFS and PFS compared to those with exon 21 L858R mutation or mutated <i>TP53</i>. Aumolertinib plus anlotinib was effective and well-tolerated as first-line therapy in EGFR-mutant NSCLC patients with BMs. Trial Registration: ClinicalTrials.gov(identifier NCT04978753, registered July 20, 2021).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月1日

查看全文
  • Jing Chen,
  • Yin Pan,
  • Meichen Li,
  • Hui Yu,
  • Baishen Zhang,
  • Mingjie Yu,
  • Xue Hou,
  • Likun Chen

摘要

The efficacy and prognosis of epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) patients with brain metastases (BMs) are poor. The third-generation EGFR-tyrosine kinase inhibitor proved to have better intracranial efficacy, which combined with anti-angiogenic drugs can further improve the efficacy. We conducted a single-arm, phase 2 clinical study (GASTO-1063) to explore the intracranial efficacy of aumolertinib plus anlotinib for NSCLC with BMs, with 87 patients enrolled. Median intracranial progression-free survival (PFS) was 30.2 months, median overall PFS was 22.5 months, and median overall survival was not reached. The intracranial objective response rate and intracranial disease control rate were 71.3% and 93.1%. Patients with exon 19 deletion or wild-type TP53 exhibited significantly longer intracranial PFS and PFS compared to those with exon 21 L858R mutation or mutated TP53. Aumolertinib plus anlotinib was effective and well-tolerated as first-line therapy in EGFR-mutant NSCLC patients with BMs. Trial Registration: ClinicalTrials.gov(identifier NCT04978753, registered July 20, 2021).